Skip to content

Ranked by human evidence

Best Peptides for Immune Support, Ranked by Evidence

Thymosin alpha-1 has the strongest human evidence for immune support: 64 randomised trials in patients with sepsis, pancreatitis and hepatitis, though the largest found no clear survival benefit. The popular inflammation peptides have far less. LL-37 has a few small ulcer trials, I could verify no VIP trial for immune use, and FDA found no human study of KPV.

A small corner with a large evidence base attached to one compound. Thymosin alpha-1 has been studied in serious clinical settings and is an approved medicine in several countries, though not in the United States - which makes where you are the deciding fact rather than a footnote.

Related: Peptides for inflammation · Peptides for gut health · Thymulin, Thymalin and Thymagen explained

Peptides for immune support, ranked by human evidence

The order is the strength of human evidence, strongest first: strong, moderate, limited, animal or lab only, then none. Ties keep the site's usual compound order. A higher rank means more and better human studies, not that a compound works for immune support, so check what each study measured.

Peptides for immune support compared: evidence level, US legal status and what human studies measured
RankCompoundEvidenceUS statusMeasured in humansGuide
1Thymosin alpha-1Strong human evidenceResearch use only64 randomised trials in sepsis, pancreatitis and hepatitis; the largest found no clear survival benefit in sepsis.Read
2ARA-290 (Cibinetide)Moderate human evidenceResearch use onlyNerve symptoms and corneal nerve fibres in small, short trials in sarcoidosis and diabetic neuropathy.Read
3LL-37Limited human dataResearch use onlyMostly small topical trials in leg and foot ulcers; the larger leg-ulcer trial found no overall benefit over placebo.Read
4VIPLimited human dataResearch use onlyDecades of trials of analogues in unrelated conditions; none verified for the immune use it is sold for.Read
5KPVAnimal / lab onlyResearch use onlyNone: FDA found no human study by any route.Read
6BronchogenAnimal / lab onlyResearch use onlyCell and animal studies only; no controlled human trials.Read
7ChonlutenAnimal / lab onlyResearch use onlyCell and animal studies only; no controlled human trials.Read
8LivagenAnimal / lab onlyResearch use onlyCell and animal studies only; no controlled human trials.Read
9CrystagenAnimal / lab onlyResearch use onlyCell and animal studies only; no controlled human trials.Read
10VilonAnimal / lab onlyResearch use onlyCell and animal studies only; no controlled human trials.Read
  1. Research peptidesResearch use only

    1. Thymosin alpha-1

    Strong human evidence

    Measured in humans: 64 randomised trials in sepsis, pancreatitis and hepatitis; the largest found no clear survival benefit in sepsis.

    Why this rating

    Sixty-four randomised controlled trials across 864 records, including a multicentre randomised trial in the BMJ in 2025 with 28-day all-cause mortality as its primary outcome. The rating reflects the design and volume of evidence, not its direction: that trial found no clear evidence of a mortality benefit in sepsis.

  2. Research peptidesResearch use only

    2. ARA-290 (Cibinetide)

    Moderate human evidence

    Measured in humans: Nerve symptoms and corneal nerve fibres in small, short trials in sarcoidosis and diabetic neuropathy.

    Why this rating

    PubMed indexes cibinetide/ARA-290 under three publications tagged as the randomised-controlled-trial publication type, and four under the clinical-trial publication type generally (NCBI E-utilities query, run 24 September 2026). That confirms multiple published human randomised trials exist, and all four are now in my citation registry. In a 2012 double-blind pilot in 22 people with sarcoidosis and small-fibre neuropathy, neuropathy symptom scores improved more on ARA-290 than placebo, while pain-intensity and fatigue scores improved equally in both groups (Heij 2012). A 2013 placebo-controlled trial in sarcoidosis reported improved neuropathic symptoms and higher corneal nerve fibre density after 28 days of daily injections (Dahan 2013). A phase 2 trial in type 2 diabetes with painful neuropathy reported improved HbA1c, blood lipids and neuropathic symptoms after 28 days (Brines 2015). In a 2017 phase 2b trial of 64 people, only the 4 mg daily dose significantly increased corneal nerve fibre area, the primary endpoint, and pain improved in all groups, including placebo (Culver 2017). All four trials are small and short, and every patient trial traces to the same sponsor, Araim Pharmaceuticals, across a narrow set of orphan-designated indications, and none led to FDA approval or a marketed product.

  3. Research peptidesResearch use only

    3. LL-37

    Limited human data

    Measured in humans: Mostly small topical trials in leg and foot ulcers; the larger leg-ulcer trial found no overall benefit over placebo.

    Why this rating

    LL-37 is naturally present in the human body, so it has a large biomarker literature: an NCBI PubMed search for "LL-37" or "cathelicidin LL-37" (queried 24 September 2026) returns over 2,500 records, 60 of them tagged as the clinical-trial publication type. The great majority of that literature measures a person's own LL-37 levels as a marker of infection or inflammation; it is not evidence that dosing a person with synthetic LL-37 is safe or effective. Four small trials have given people LL-37: two of a topical solution on venous leg ulcers (34 and 148 people; the larger found no significant improvement in healing over placebo across the whole group), one of a cream on diabetic foot ulcers, and one of an oral product of bacteria engineered to make LL-37 in people in hospital with COVID-19. None tested an injection. FDA's bulk drug substance review states it lacks sufficient safety-related information regarding cathelicidin LL-37 to know whether the drug would cause harm when administered to humans, and cites nonclinical findings raising reproductive and protumorigenic concerns.

  4. Research peptidesResearch use only

    4. VIP

    Limited human data

    Measured in humans: Decades of trials of analogues in unrelated conditions; none verified for the immune use it is sold for.

    Why this rating

    VIP is one of the most extensively studied endogenous neuropeptides: an NCBI PubMed title/abstract search for "vasoactive intestinal peptide" (queried 24 September 2026) returns 8,389 records, 111 of them tagged as the clinical-trial publication type. That trial base spans decades of different synthetic analogues (notably aviptadil) and unrelated indications - respiratory, cardiovascular, reproductive - and none of the individual studies are curated in this site's verified source registry, so no specific trial finding is reported on this page. For the immune-modulation use it is actually sold for, I could not verify any completed human trial establishing benefit.

  5. Research peptidesResearch use only

    5. KPV

    Animal / lab only

    Measured in humans: None: FDA found no human study by any route.

    Why this rating

    Cells and animals only. FDA's July 2026 briefing document states that neither the nominator nor FDA identified any clinical study or human exposure data for KPV by any route. A PubMed search for KPV as a peptide (queried 23 September 2026) returns 110 records and zero indexed under a clinical-trial or randomised-controlled-trial publication type.

  6. Research peptidesResearch use only

    6. Bronchogen

    Animal / lab only

    Measured in humans: Cell and animal studies only; no controlled human trials.

    Why this rating

    PubMed returns 12 records for "Bronchogen"; five are unrelated case reports about bronchogenic cysts, a coincidental word match, not the peptide. Of the seven real records, none is a clinical trial or a study in a living human being. The most substantive result is real: two related publications report that a month of Bronchogen treatment reduced neutrophilic inflammation and restored bronchial epithelium structure in a rat model of nitrogen-dioxide-induced chronic obstructive pulmonary disease. The rest of the record is in vitro DNA-binding and cell-culture work.

  7. Research peptidesResearch use only

    7. Chonluten

    Animal / lab only

    Measured in humans: Cell and animal studies only; no controlled human trials.

    Why this rating

    PubMed returns exactly one record for "Chonluten": a 2022 in vitro study testing it alongside four other Khavinson peptides on a human monocyte cell line, finding reduced inflammatory cytokine release and reduced cell adhesion. No animal study, no clinical trial and no randomised trial of any kind exists for Chonluten specifically.

  8. Research peptidesResearch use only

    8. Livagen

    Animal / lab only

    Measured in humans: Cell and animal studies only; no controlled human trials.

    Why this rating

    PubMed returns 19 records for "Livagen". The records I verified are laboratory work: cultured rat hepatocytes, organotypic liver culture, a review of animal models of liver fibrosis and hepatitis, and lymphocytes or serum donated by elderly volunteers and tested outside the body. None is tagged as a clinical trial or randomised controlled trial, and none reports dosing a living human being.

  9. Research peptidesResearch use only

    9. Crystagen

    Animal / lab only

    Measured in humans: Cell and animal studies only; no controlled human trials.

    Why this rating

    PubMed indexes exactly one paper that studies Crystagen by name: a Russian-language report on several short peptides tested together in the ageing spleen. Its abstract names no species and does not say whether the work was done in living animals or in tissue culture. It is not a clinical trial, not a randomised trial, and not a study in a living, dosed person. I could not find any second paper, in any language, that tests Crystagen specifically.

  10. Research peptidesResearch use only

    10. Vilon

    Animal / lab only

    Measured in humans: Cell and animal studies only; no controlled human trials.

    Why this rating

    Vilon has real, checkable cell-culture evidence under its own name. One study names it directly as one of five Khavinson-group peptides tested on human THP-1 monocyte/macrophage cells, where it modulated proliferative signalling. A second, titled around "Vilon and its analogue," reports that dipeptides increased a T-cell differentiation marker in cultured human and animal thymus cells. Both are cell-culture experiments, not animal or human trials, and both come from the same small Russian research tradition.

Common questions about peptides for immune support

What is the strongest peptide for inflammation?

I found no peptide with strong human evidence as a general anti-inflammatory. Thymosin alpha-1 has the largest trial record, in patients with sepsis, pancreatitis and hepatitis. KPV, often sold for gut inflammation, reduced inflammation in 2 mouse colitis models, but FDA found no human study of it by any route.

Is BPC-157 an anti-inflammatory?

The human evidence does not show it. Its one placebo-controlled human trial, in 53 people with ulcerative colitis, an inflammatory bowel disease, did not show a significant benefit and was published only as a meeting abstract. Almost all of its efficacy data comes from rats.

Does thymosin alpha-1 boost the immune system?

It is approved in a number of countries, classically for chronic hepatitis B, but not in the United States. Its 64 randomised trials are in patients with conditions such as sepsis and hepatitis, not healthy adults. The largest, published in the BMJ in 2025, found no clear survival benefit in sepsis.

Is thymosin alpha-1 legal in the US?

It is not FDA-approved: FDA's December 2024 briefing says it has approved no drug product containing it. In the US it is sold as a research chemical, while several other countries license it as a medicine, so where you are decides its status.

What is ARA-290?

An 11-amino-acid peptide built from a piece of erythropoietin. Its developer ran small, short randomised trials in sarcoidosis and diabetic neuropathy, measuring nerve symptoms and corneal nerve fibres, and won 4 FDA orphan drug designations. None led to approval.

Guides on peptides for immune support

Best peptides for other goals